Mvasi (bevacizumab-awwb) is a biosimilar to Avastin (bevacizumab).
Mvasi is not interchangeable with Avastin. The prescriber must write a prescription specifically for Mvasi.
A biosimilar, according to the FDA, is a biological product that is highly similar to an FDA-approved biological product, known as a reference product (in this case Avastin), and has no clinically meaningful differences in terms of safety and effectiveness.
See Biosimilar and Interchangeable Biologics: More Treatment Choices
Mvasi has the same approved indications as Avastin, with the exception of hepatocellular carcinoma.
| Avastin | Mvasi | |
|---|---|---|
| Generic Name | bevacizumab | bevacizumab-awwb |
| How Supplied |
|
|
| Indications |
|
|
Mvasi was approved in 2017 as the first biosimilar to Avastin. A second Avastin biosimilar called Zirabev (bevacizumab-bvzr) was approved in 2019, and a third called Alymsys (bevacizumab-maly) was approved in 2022.